Get started
Author

Jihao Zhou

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial
2013 · Christopher Chapple, Karl-Dietrich Sievert, et al. · European Urology · 416
Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial
2010 · Roger Dmochowski, Christopher Chapple, et al. · The Journal of Urology · 407
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
2017 · J.T. Lear, M.R. Migden, et al. · Journal of the European Academy of Dermatology and Venereology · 195
PDF
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo‐controlled dose‐finding study in idiopathic overactive bladder
2011 · Eric Rovner, Michael Kennelly, et al. · Neurourology and Urodynamics · 177
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects
2006 · Carlo L. Bello, Laurie Sherman, et al. · Anti-Cancer Drugs · 136
A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia
2012 · Michael Marberger, Emmanuel Chartier-Kastler, et al. · European Urology · 101
OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial
2012 · Clare J. Fowler, Stephen Auerbach, et al. · European Urology · 90
OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
2014 · K.‐D. Sievert, C. Chapple, et al. · International Journal of Clinical Practice · 63
PDF
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial
2023 · Richard B Warren, Adam Reich, et al. · British Journal of Dermatology · 58
Dose response with onabotulinumtoxinA for post‐stroke spasticity: A pooled data analysis
2010 · Stuart A. Yablon, Mitchell F. Brin, et al. · Movement Disorders · 32
Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB
2012 · Linda Brubaker, Angelo Gousse, et al. · International Urogynecology Journal · 29
Non-compartment model to compartment model pharmacokinetics transformation meta-analysis – a multivariate nonlinear mixed model
2010 · Zhiping Wang, Seongho Kim, et al. · BMC Systems Biology · 26
PDF
Dose-Escalation Study of Sonidegib (Lde225) Plus Buparlisib (Bkm120) in Patients (Pts) with Advanced Solid Tumors
2014 · Q.S. Chu, A. Mahipal, et al. · Annals of Oncology · 13
PDF
LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical Trials
2024 · Sue Ellen Cox, Joely Kaufman-Janette, et al. · Dermatologic Surgery · 8
34617 Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: Design of a pivotal phase 3 clinical trial and a long-term extension study
2022 · Johann E. Gudjonsson, Bruce Randazzo, et al. · Journal of the American Academy of Dermatology · 8
Statistical considerations in bioequivalence of two area under the concentration–time curves obtained from serial sampling data
2013 · Steven Y. Hua, D. L. Hawkins, et al. · Journal of Applied Statistics · 7
Botulinum Toxin a (botox®) Demonstrates Dose-dependent Improvements in Health-related Quality-of-life Measures in Idiopathic Overactive Bladder
2009 · Clare Fowler, Stephen Auerbach, et al. · The Journal of Urology · 6
1367 Onabotulinumtoxina in Patients With Overactive Bladder and Urinary Incontinence: Consistent Effect Over Repeat Treatment
2013 · Victor W. Nitti, Karl-Dietrich Sievert, et al. · The Journal of Urology · 5
1533 Urodynamic Results and Clinical Outcomes With Intravesical Botulinum Toxin a (onabotuliumtoxina) in a Randomized, Placebo Controlled Dose-finding Study in Idiopathic Overactive Bladder
2010 · Eric Rovner, Michael Kennelly, et al. · The Journal of Urology · 4
Drug–Drug Interaction Prediction Assessment
2009 · Jihao Zhou, Zhaohui Qin, et al. · Journal of Biopharmaceutical Statistics · 4
A new probabilistic rule for drug–dug interaction prediction
2009 · Jihao Zhou, Zhaohui Qin, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 4
Cost-Efficient Higher-Order Crossover Designs in Comparative Bioavailability Studies
2006 · Jihao Zhou, Ying Yuan, et al. · Clinical Pharmacokinetics · 4
Cost‐efficient higher‐order crossover designs for two‐treatment clinical trials
2005 · Ying Yuan, Jihao Zhou · Pharmaceutical Statistics · 4
First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor, in EGFR -mutant ( EGFR m) NSCLC.
2026 · Xiuning Le, Alexander I. Spira, et al. · Journal of Clinical Oncology · 2
PDF
Mp38-01 Long-term Efficacy and Safety of Repeat Onabotulinumtoxina Treatment in Overactive Bladder Syndrome and Urinary Incontinence: Third Interim Analysis, Median 2.4 Year Follow-up
2014 · Victor Nitti, Christopher Chapple, et al. · The Journal of Urology · 2
Works count: 54
Citation count: 1,812
H-index: 13
I10-index: 13
Year
Topic
Type